Back to all companies
Sign in
Back to all companies
PreDxion Bio logo

PreDxion Bio

Summer 2017Inactive

Rapid, scalable diagnostic for SARS-CoV-2 and beyond

Save
PreDxion Bio logo

PreDxion Bio

Summer 2017Inactive

Rapid, scalable diagnostic for SARS-CoV-2 and beyond

Save
Company details

PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale.

PreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.

Location
San Francisco, CA, USA; South San Francisco, CA, USA
Founded
Unknown
Category
Microfluidics
YC Directory Pagewww.predxionbio.com
Founders
  • WM
    Walker McHugh
    Founder
    X / TwitterLinkedIn
  • TC
    Timothy Cornell
    Founder
    LinkedIn

PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale.

PreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.

Location
San Francisco, CA, USA; South San Francisco, CA, USA
Founded
Unknown
Category
Microfluidics
YC Directory Pagewww.predxionbio.com
Founders
  • WM
    Walker McHugh
    Founder
    X / TwitterLinkedIn
  • TC
    Timothy Cornell
    Founder
    LinkedIn
Pro

Upgrade to Pro, then request the PreDxion Bio teardown.

This company does not have a completed analysis yet. Choose a Pro plan first, then use one of your 5 monthly research requests to have our agent investigate PreDxion Bio. The full teardown, rebuild plan, and technical specs unlock when it lands.

  • Use Pro to request the first PreDxion Bio teardown and keep the finished report in your account.
  • Read every completed teardown and rebuild plan already in the database.
  • Unlock implementation-ready technical specs and 5 fresh research requests each month.

Choose your Pro plan

$20/ month

Find one worth rebuilding, get the teardown, open the implementation-ready specs, and use fresh report requests when you want deeper research.

See Pro plans
Full teardown library
Specs for every company
5 fresh requests / month
CLI for agent imports
Startups.RIP — Dead startups, alive ideas
PricingContactPrivacyGot feedback? DM @oscrhong